Phase 1 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a written consent form agreeing to take part in the trial
• People aged 18 or older, of any gender
• People with a life expectancy of at least 12 weeks
• People who are generally well enough to carry out light activity and care for themselves, based on a standard medical fitness scale (ECOG score of 0 or 1)
• For one part of the trial (Part 1): People with an advanced or metastatic solid tumour (confirmed by laboratory testing of tissue) who have already tried all standard available treatments, and whose tumour has a specific genetic change called a BRCA mutation and/or a deficiency in a DNA repair process called homologous recombination
• For another part of the trial (Part 2): People with confirmed locally advanced or metastatic ovarian cancer, or breast cancer that tests negative for a protein called HER2, and whose tumour has a BRCA mutation and/or a homologous recombination repair deficiency
• People who have at least one tumour that can be measured using standard imaging criteria
• People without serious problems affecting the blood, heart, lungs, liver, or kidneys (beyond the cancer being treated)
• People whose organ function and bone marrow function meet required levels based on blood tests

Who may not be able to join:

• People who have previously used or are currently using a type of drug called a DNA Polymerase Theta (POLQ) inhibitor
• People with a history of another cancer, unless it was fully treated and there has been no sign of it returning or spreading for at least the past 5 years
• People with cancer that has spread to the brain or the lining around the brain and spinal cord, if it is causing symptoms or has not been adequately controlled
• People who have or are suspected to have certain blood or bone marrow conditions called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML)
• People with difficulty swallowing, persistent nausea and vomiting, poor nutrient absorption, certain bowel conditions (such as Crohn's disease, ulcerative colitis, or short bowel syndrome), or other conditions that may affect how the body absorbs medication
• People who have recently received certain anti-cancer medications within a specific timeframe before starting the trial (confirm with trial site)
• People who have used, or need to continue using, certain medications that strongly affect the way the body processes drugs (specifically, strong inhibitors or inducers of enzymes called CYP3A4, BCRP, or P-gp) within two weeks before or during the trial
• People with serious health conditions, abnormal test results, or other factors that the trial doctor considers would make participation unsafe or unsuitable

Important: Always verify eligibility with the trial site directly before applying.